Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia

Field, Emma J., Vally, Hassan, Grimwood, Keith and Lambert, Stephen B. (2010) Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. Pediatrics, 126 3: e506-e512. doi:10.1542/peds.2010-0443

Author Field, Emma J.
Vally, Hassan
Grimwood, Keith
Lambert, Stephen B.
Title Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia
Journal name Pediatrics   Check publisher's open access policy
ISSN 0031-4005
Publication date 2010-09-03
Sub-type Article (original research)
DOI 10.1542/peds.2010-0443
Volume 126
Issue 3
Start page e506
End page e512
Total pages 6
Place of publication Elk Grove Village, United States
Publisher American Academy of Pediatrics
Collection year 2011
Language eng
Subject 11 Medical and Health Sciences
Formatted abstract
OBJECTIVE: A publicly funded, universal infant pentavalent rotavirus vaccine (RV5) program was implemented in Queensland, Australia, in mid-2007. We sought to assess vaccine effectiveness (VE) of 3 doses of RV5 at preventing rotavirus and nonrotavirus acute gastroenteritis (AGE) hospitalizations in the first birth cohort and impact on hospitalizations in all age groups.

METHODS: Hospitalization rates for rotavirus and nonrotavirus AGE in all age groups before and after RV5 introduction were compared. Population vaccine coverage, hospitalization data, and individual vaccination status were obtained from routinely collected, publicly funded state- and nationally based data sets. Data linkage was performed to calculate 3-dose VE for preventing hospitalization in the eligible age group.

RESULTS: RV5 coverage in the first eligible birth cohort was 89.6% for at least 1 dose and 73.1% for 3 doses. Three-dose VE for preventing nonrotavirus AGE hospitalization was 62.3% to 63.9% (any/primary diagnosis) and 89.3% to 93.9% (any/primary diagnosis) for rotavirus hospitalizations. After program implementation, there were immediate and sustained reductions in rotavirus hospitalizations for those who were younger than 20 years and nonrotavirus AGE-coded hospitalizations for those who were younger than 5 years.

RV5 is highly effective at preventing rotavirus hospitalizations in a developed country setting, confirming efficacy figures from the pivotal clinical trial. Additional direct and indirect effects are substantial and include reductions in nonrotavirus AGE hospitalizations in vaccinated age groups and rotavirus and nonrotavirus AGE hospitalization rates in older age groups.
Copyright © 2010 by the American Academy of Pediatrics
Keyword Pentavalent rotavirus vaccine
Screening method
Vaccine effectiveness
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2011 Collection
School of Medicine Publications
Clinical Medical Virology Centre Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 63 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 73 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Sep 2010, 15:07:47 EST by Thelma Whitbourne on behalf of Child Health Research Centre